Novartis

New $1b NIH center will tackle early-stage drug development to ease industry risk of failure

Monday, February 7, 2011 07:00 AM

A billion-dollar U.S. government drug development center, which will focus on moving potential new discoveries out of the lab and into early-phase trials, could help biopharmaceutical companies improve their success rate in developing new treatments by reducing the risk of failure in early-stage research.

More... »

Clinical Trial Activity in Russia Dipped in 2009

Friday, March 5, 2010 06:56 AM

According to Russia-based contract research organization (CRO) Synergy Research Group’s Annual Orange Report, Russia’s regulatory agency Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (RosZdravNadzor, RZN) approved 577 new clinical trials during 2009, 6% fewer than in 2008. Sixty percent, or 348 of the new studies, were multinational multi-center trials, down 4% from 2008.

More... »

CT Approvals Down, Global Participation Up in Russia Q2

Wednesday, September 2, 2009 07:19 AM

According to an Orange Paper released by Russia-based CRO, Synergy Research Group, Russia’s health agency, the Federal Service on Surveillance in Healthcare and Social Development (RosZdraNadzor, RZN) approved only 129 new clinical trials, including local and bioequivalence studies, during Q2 2009, representing a 17% decrease from Q2 last year. The percentage of approved multinational clinical trials increased slightly, however, to 65% of the total during this time period.

More... »

CenterWatch Monthly May 2009

Friday, May 1, 2009 11:00 AM

U.S. Sites Rate Novo Nordisk, Novartis and Eisai as Top Sponsors in 2009

More... »

Fighting The Logjam In LatAm Drug Trials

Monday, September 18, 2006 10:24 AM

Clinical research in Latin America has grown significantly over the past 10 years but obstacles to continued growth still exist. In our first-ever survey of investigative sites in Latin America, we at Thomson CenterWatch found that bottlenecks at the site level continue to hinder growth of clinical research in the region as researchers strive to improve the system.

More... »